Skeletal preservation in prostate cancer: The changing role of the urologist

被引：2

作者：

Clarke, Noel W. ^{[1
]}

机构：

[1] Christie Hosp NHS Trust, Dept Surg, Manchester M20 4BX, Lancs, England

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 17期

关键词：

D O I：

10.1016/j.eursup.2006.06.019

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：871 / 872

页数：2

共 3 条

[1] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Chen, B .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) :1458-1468

[2] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [J].

Saad, F ;

Gleason, DM ;

Murray, R ;

Tchekmedyian, S ;

Venner, P ;

Lacombe, L ;

Chin, JL ;

Vinholes, JJ ;

Goas, JA ;

Zheng, M .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) :879-882

[3] Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer [J].

Smith, MR ;

Eastham, J ;

Gleason, DM ;

Shasha, D ;

Tchekmedyian, S ;

Zinner, N .

JOURNAL OF UROLOGY, 2003, 169 (06) :2008-2012

← 1 →